Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Achaogen Inc    AKAO

ACHAOGEN INC (AKAO)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
11.94(c) 11.58(c) 11.83(c) 11.59(c) 11.54(c) Last
1 355 573 1 269 911 841 497 839 734 450 755 Volume
-3.86% -3.02% +2.16% -2.03% -0.43% Change
More quotes
Financials ($)
Sales 2017 11,1 M
EBIT 2017 -119 M
Net income 2017 -123 M
Finance 2017 106 M
Yield 2017 -
Sales 2018 15,2 M
EBIT 2018 -144 M
Net income 2018 -144 M
Finance 2018 134 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 34,6x
EV / Sales2018 23,4x
Capitalization 489 M
More Financials
Company
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections.It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood... 
More about the company
Surperformance© ratings of Achaogen Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACHAOGEN INC
01/11 ACHAOGEN, INC. (NASDAQ : AKAO) Files An 8-K Regulation FD Disclosure
01/11 ACHAOGEN INC : Regulation FD Disclosure, Financial Statements and Exhibits (form..
01/03 Achaogen to Present at J.P. Morgan Healthcare Conference
01/03 ACHAOGEN : Announces FDA Acceptance of New Drug Application with Priority Review..
01/02 Achaogen Announces FDA Acceptance of New Drug Application with Priority Revie..
01/02 Achaogen Announces Positive Top-Line Results from First Clinical Trial of Ora..
2017 ACHAOGEN : Announces New Employment Inducement Grants
2017 ACHAOGEN : Announces New Employment Inducement Grants
2017 Achaogen Announces New Employment Inducement Grants
2017 ACHAOGEN : Appoints Blake Wise Chief Executive Officer
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
01/19Shorts still in FULL control of $AKAO 
01/15Get the latest news and updates for $AKAO $CVEO $CYBR $CMCM $FCB automaticall.. 
01/12$AKAO - Achaogen #AKAO Rating Lowered to Sell at Zacks Investment Research  
01/12Achaogen $AKAO Rating Lowered to Sell at Zacks Investment Research  
01/12Somewhat Positive Media Coverage Somewhat Unlikely to Impact Achaogen $AKAO S.. 
More tweets
Qtime:55
News from SeekingAlpha
01/16 2018 STRATEGIC OUTLOOK : Will Fortune Favor The Bold In Biotech?
01/12 Achaogen (AKAO) Presents At 36th Annual J.P. Morgan Healthcare Conference - S..
01/10 After Hours Gainers / Losers (1/10/2018)
01/09 Zymeworks - Protein Proficiency At A Discount
01/09 YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici..
Chart ACHAOGEN INC
Duration : Period :
Achaogen Inc Technical Analysis Chart | AKAO | US0044491043 | 4-Traders
Technical analysis trends ACHAOGEN INC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 25,0 $
Spread / Average Target 117%
EPS Revisions
Managers
NameTitle
Blake Wise President, CEO, COO & Director
Bryan E. Roberts Chairman
Tobin Schilke CFO & Principal Accounting Officer
Kenneth J. Hillan Director, President-Research & Development
Lee Swem Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACHAOGEN INC7.91%489
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-0.50%39 890
VERTEX PHARMACEUTICALS4.76%39 754
GENMAB10.50%11 455
BLUEBIRD BIO INC2.25%8 346